Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.

Pajares B, Torres E, Trigo JM, Sáez MI, Ribelles N, Jiménez B, Alba E.

Clin Transl Oncol. 2012 Feb;14(2):94-101. doi: 10.1007/s12094-012-0767-5. Review.

PMID:
22301397
2.

Tyrosine kinases as targets in cancer therapy - successes and failures.

Traxler P.

Expert Opin Ther Targets. 2003 Apr;7(2):215-34. Review.

PMID:
12667099
3.

Tyrosine kinase inhibitors in pediatric malignancies.

Skolnik JM, Adamson PC.

Cancer Invest. 2007;25(7):606-12. Review.

PMID:
17952738
4.

Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.

Carmi C, Mor M, Petronini PG, Alfieri RR.

Biochem Pharmacol. 2012 Dec 1;84(11):1388-99. doi: 10.1016/j.bcp.2012.07.031. Epub 2012 Aug 4. Review.

PMID:
22885287
5.

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases.

van der Kuip H, Wohlbold L, Oetzel C, Schwab M, Aulitzky WE.

Am J Pharmacogenomics. 2005;5(2):101-12. Review.

PMID:
15813673
6.

Tyrosine kinase inhibitors.

Natoli C, Perrucci B, Perrotti F, Falchi L, Iacobelli S; Consorzio Interuniversitario Nazionale per Bio-Oncologia (CINBO).

Curr Cancer Drug Targets. 2010 Aug;10(5):462-83. Review.

PMID:
20384577
7.

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.

Nelson MH, Dolder CR.

Ann Pharmacother. 2006 Feb;40(2):261-9. Epub 2006 Jan 17. Review.

PMID:
16418322
8.

Meeting report: targeting the kinome--20 years of tyrosine kinase inhibitor research in Basel.

Bozulic L, Morin P Jr, Hunter T, Hemmings BA.

Sci STKE. 2007 Feb 20;2007(374):pe8.

PMID:
17317657
9.

Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.

Josephs DH, Fisher DS, Spicer J, Flanagan RJ.

Ther Drug Monit. 2013 Oct;35(5):562-87. doi: 10.1097/FTD.0b013e318292b931. Review.

PMID:
24052062
10.

Role of tyrosine kinase inhibitors in cancer therapy.

Arora A, Scholar EM.

J Pharmacol Exp Ther. 2005 Dec;315(3):971-9. Epub 2005 Jul 7. Review.

11.

Novel tyrosine kinase inhibitors in the treatment of cancer.

Ocana A, Serrano R, Calero R, Pandiella A.

Curr Drug Targets. 2009 Jun;10(6):575-6. No abstract available.

PMID:
19519359
12.

Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.

Steeghs N, Nortier JW, Gelderblom H.

Ann Surg Oncol. 2007 Feb;14(2):942-53. Epub 2006 Nov 14. Review.

PMID:
17103252
13.

Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond.

Bologna M, Vicentini C, Muzi P, Pace G, Angelucci A.

Curr Med Chem. 2011;18(19):2827-35. Review.

PMID:
21651496
14.

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Hartmann JT, Haap M, Kopp HG, Lipp HP.

Curr Drug Metab. 2009 Jun;10(5):470-81. Review.

PMID:
19689244
15.

Specific cell-signal targets for cancer chemotherapy.

Aszalos A.

Arch Pharm Res. 2002 Feb;25(1):1-10. Review.

PMID:
11885686
16.
17.

Therapeutic protein kinase inhibitors.

Grant SK.

Cell Mol Life Sci. 2009 Apr;66(7):1163-77. doi: 10.1007/s00018-008-8539-7. Review.

PMID:
19011754
18.

Cardiotoxicity induced by tyrosine kinase inhibitors.

Orphanos GS, Ioannidis GN, Ardavanis AG.

Acta Oncol. 2009;48(7):964-70. doi: 10.1080/02841860903229124. Review.

PMID:
19734999
19.

Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Engelman JA, Settleman J.

Curr Opin Genet Dev. 2008 Feb;18(1):73-9. doi: 10.1016/j.gde.2008.01.004. Epub 2008 Mar 5. Review.

PMID:
18325754
20.

[Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].

Joensuu H.

Duodecim. 2012;128(21):2261-8. Review. Finnish.

PMID:
23210289

Supplemental Content

Support Center